✓ Bengaluru
✓ ZCCK Registered
✓ ZCCK Registered
Fatty liver (MASLD) now affects 1 in 3 adults in India — most have no symptoms. Without proper staging and monitoring, it can silently progress through fibrosis to cirrhosis and liver cancer. Expert assessment prevents that journey.
Fatty liver disease — now officially called MASLD (Metabolic-Associated Steatotic Liver Disease) — occurs when more than 5% of liver cells accumulate fat. It is strongly linked to metabolic syndrome: obesity, type 2 diabetes, high triglycerides, hypertension, and insulin resistance.
The older term NAFLD (Non-Alcoholic Fatty Liver Disease) is still widely used. The key distinction: MASLD is defined by metabolic risk factors, while MASH (Metabolic-Associated SteatoHepatitis — formerly NASH) refers to the inflammatory form that drives fibrosis progression.
In India, prevalence is estimated at 32–38% of adults in urban populations — driven by a combination of genetic predisposition (South Asians develop metabolic liver disease at lower BMIs than Western populations), high-carbohydrate diets, and sedentary lifestyles.
20% of people with MASH will develop cirrhosis over 10–20 years. 15–25% of those will develop liver cancer (HCC).
Different tools answer different questions. Accurate staging drives the right management decision.
ALT, AST, GGT, ALP, albumin, bilirubin, CBC, fasting lipids, HbA1c, TSH. The FIB-4 score (calculated from age + ALT + AST + platelets) is validated as an initial fibrosis risk triage tool. FIB-4 below 1.3 is low risk; above 2.67 is high risk for advanced fibrosis.
Detects hepatic steatosis, liver size, echogenicity, and signs of portal hypertension (splenomegaly, ascites). Ultrasound cannot quantify fat accurately below 30% steatosis, and cannot reliably detect fibrosis stages F0–F2.
Measures liver stiffness in kPa (fibrosis stage) and CAP score in dB/m (fat content percentage). Takes 5 minutes, no needles, results immediate. Highly accurate for F3–F4 fibrosis. Available at Dhaara Liver Clinic, Yelahanka. Normal kPa is <5.3; cirrhosis threshold is >12–15 kPa depending on cause.
Gold standard for staging MASH and fibrosis — distinguishes Stage F1 from F2, quantifies steatosis and hepatocyte ballooning, rules out co-existing liver diseases. Required when diagnosis is uncertain, when starting pharmacotherapy for fibrosis, or when Fibroscan results are discordant with clinical picture.
Magnetic Resonance Imaging — Proton Density Fat Fraction. Most accurate non-invasive measure of liver fat content. Used in clinical trials and when Fibroscan is technically limited (BMI > 40, narrow intercostal space). Not routinely needed in clinical practice.
FIB-4 = (Age × AST) ÷ (Platelets × √ALT). Your doctor or lab report may include this automatically. Here is how to interpret it:
Note: FIB-4 thresholds differ in patients over 65 years (upper normal rises to 2.0). Always interpret in clinical context.
There is no single pill for MASLD. Effective treatment combines multiple interventions tailored to your fibrosis stage and metabolic profile.
7% body weight loss reduces liver inflammation. 10% weight loss reduces liver fat by 50–80% and can reverse MASH. 15% sustained weight loss can partially reverse early fibrosis. A structured programme with a dietitian and liver specialist gives better outcomes than self-directed dieting.
Mediterranean-style diet: olive oil, vegetables, whole grains, fish, legumes. In Indian context: replace white rice with millets (ragi, jowar, bajra) and brown rice; eliminate maida, biscuits, and packaged snacks; stop sugar-sweetened beverages; increase leafy vegetables; moderate fruit intake (avoid fruit juices). Coffee (2–3 cups/day, no sugar) has documented liver-protective effects.
150–300 minutes per week of moderate aerobic exercise (brisk walking, cycling, swimming). Resistance training 2–3 times per week additionally reduces liver fat. Even without weight loss, exercise reduces liver inflammation and improves insulin sensitivity. The goal is consistent activity — not intense exercise.
Aggressive management of all metabolic risk factors. GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) significantly reduce liver fat and inflammation. SGLT2 inhibitors (empagliflozin, dapagliflozin) benefit MASLD in diabetic patients. Statins are safe and beneficial for dyslipidaemia in MASLD — the old concern about statin hepatotoxicity was unfounded.
Vitamin E (800 IU/day) for non-diabetic MASH with F2+ fibrosis. Pioglitazone for diabetic MASH. Resmetirom (Rezdiffra) — the first FDA-approved drug specifically for MASH with fibrosis stage F2–F3 — is now available and targets liver fat and fibrosis simultaneously. Patient selection is critical.
All patients with MASLD cirrhosis require 6-monthly liver ultrasound + AFP (alpha-fetoprotein). MASLD cirrhosis is now a leading cause of liver cancer in India. Liver cancer caught at stage 1 is curable. Caught at stage 3–4 has limited treatment options. Surveillance saves lives — do not skip appointments.
Misinformation is widespread. Here are common myths Dr. Srinivas encounters from patients in North Bangalore.
"Ghee and coconut oil are natural and safe for fatty liver."
Both are high in saturated fat. Ghee and coconut oil raise LDL and worsen metabolic syndrome. Moderate ghee (1 tsp/day) is acceptable for most, but large quantities accelerate fatty liver progression.
"I don't drink alcohol, so my liver is fine."
MASLD has nothing to do with alcohol. It is driven entirely by metabolic factors — excess body fat, insulin resistance, and diet. Teetotallers can have severe fatty liver and cirrhosis.
"Fruit juice is healthy, not harmful."
Commercial fruit juices are concentrated fructose — metabolised entirely in the liver and directly drives hepatic fat synthesis (de novo lipogenesis). Even "100% natural" juices worsen fatty liver. Eat whole fruit instead.
"Liver tablets and Ayurvedic medicines will clean my liver."
Many "liver tonic" herbal supplements have no clinical evidence and some cause drug-induced liver injury (DILI). The liver cannot be "cleansed." Lifestyle change is the only proven treatment. Always tell your liver specialist about every supplement.
"Brown rice is fine; only white rice is bad."
Brown rice is better than white rice (higher fibre, lower glycaemic index), but it is still a high-calorie carbohydrate. For fatty liver patients, total carbohydrate reduction matters more than simply switching rice varieties. Millets are a significantly better alternative.
"If my doctor is not worried, I can ignore the ultrasound finding."
Fatty liver on ultrasound without symptoms does NOT mean it is harmless. It means you are at the earliest — and most treatable — stage of a condition that can take 10–20 years to cause serious harm. Early intervention prevents cirrhosis. Ignoring it is how patients end up needing liver transplants.
Indeterminate fibrosis risk on blood tests — requires Fibroscan for proper staging. GP cannot manage this accurately without specialist input.
Indicates significant fibrosis (F2 or above). Pharmacotherapy decisions, biopsy planning, and surveillance scheduling require a hepatologist or liver specialist.
This combination doubles the rate of fibrosis progression. All diabetic patients with fatty liver need dedicated liver specialist co-management alongside their diabetologist.
Persistently elevated ALT or AST without clear explanation warrants specialist workup. Many causes co-exist with MASLD (autoimmune hepatitis, Wilson's disease, alpha-1 antitrypsin deficiency).
These findings suggest advanced fibrosis or early cirrhosis. This is not the time for watchful waiting — immediate specialist assessment is required.
If you have lost weight but ALT/AST have not improved after 6 months, there may be a different underlying cause or fibrosis that needs specialist assessment.
Fibroscan (transient elastography) is the most important test for anyone with fatty liver on ultrasound. It provides two critical measurements in a single 5-minute, painless scan:
No needle, no fasting required, no radiation. Results are available immediately. Dr. Srinivas interprets Fibroscan results in the context of your clinical history, blood tests, and ultrasound findings — not in isolation.
Fibroscan is available at Dhaara Liver Clinic, Yelahanka, Bangalore. It is the key investigation for anyone referred with fatty liver or suspected MASLD.
Dr. Srinivas Bojanapu is a Liver Transplant and HPB Surgeon based at Dhaara Liver Clinic, Yelahanka, North Bangalore. For MASLD patients, his approach integrates:
Yes — simple steatosis (Stage 1) and early MASH (Stage 2) are fully reversible with sustained 7–10% body weight loss, metabolic control, and dietary change. Fibrosis stages F1–F2 can stabilise and partially reverse. F3 (bridging fibrosis) can sometimes regress with treatment. F4 (cirrhosis) is not reversible but can be managed to prevent decompensation. The earlier you intervene, the better the outcome.
Yes, and this is one of the most common misconceptions. Normal liver enzymes do NOT exclude significant fatty liver or fibrosis. Up to 60% of people with MASLD have normal ALT and AST at any given time. LFTs are insensitive for staging fatty liver disease. You need a Fibroscan and a FIB-4 score for accurate risk assessment. Please see a liver specialist — do not be reassured by normal LFTs alone.
Fibroscan is a painless, 5-minute ultrasound-based scan that measures two things: how stiff your liver is (fibrosis score in kPa) and how much fat is in it (CAP score in dB/m). No preparation needed, no needles, no radiation. Any adult with fatty liver on ultrasound should have a Fibroscan to accurately stage their disease. It is available at Dhaara Liver Clinic in Yelahanka. The results, interpreted together with your blood tests, tell us exactly what stage you are at and what treatment you need.
FIB-4 is calculated from four routine blood test values: your age, ALT, AST, and platelet count. It estimates the probability of advanced liver fibrosis. A score below 1.3 means low risk of fibrosis and can be monitored. Between 1.3 and 2.67 is indeterminate — you need a Fibroscan. Above 2.67 indicates high probability of significant fibrosis and you should see a liver specialist urgently. Many labs now automatically calculate and report FIB-4; if yours does not, ask your doctor to calculate it.
Yes. MASLD is now one of the fastest-growing causes of hepatocellular carcinoma (HCC) worldwide and in India. If MASLD progresses to cirrhosis, the annual HCC risk is 1–3%. Rarely, MASLD can cause HCC even before cirrhosis develops. All patients with MASLD cirrhosis must undergo 6-monthly HCC surveillance — liver ultrasound plus AFP blood test. Liver cancer caught early (stage 1) is curative; caught late, treatment options are very limited.
A Mediterranean-style diet is the most evidence-based approach, adapted for Indian eating patterns: replace white rice with millets (ragi, jowar, bajra) or brown rice; completely eliminate maida, bakery products, biscuits, and deep-fried snacks; stop all sugar-sweetened beverages including packaged fruit juices; increase vegetables, dal, and whole legumes; use olive oil or cold-pressed groundnut oil in moderate quantities; eat lean protein (fish, chicken, eggs, low-fat dairy, legumes). Coffee (2–3 cups/day without sugar) has documented liver-protective effects in multiple studies. Avoid extreme detox diets — rapid weight loss can actually worsen liver inflammation temporarily.
This is an important safety question. Many herbal supplements marketed for liver health can actually cause drug-induced liver injury (DILI) and worsen your condition. Products containing kava, pennyroyal, green tea extract (high dose), certain traditional Ayurvedic formulations with heavy metals, and even high-dose turmeric supplements have documented hepatotoxicity. "Natural" does not mean safe for the liver. Always disclose every supplement, herbal product, and over-the-counter medicine to Dr. Srinivas. There is no supplement that reverses fatty liver — lifestyle change is the only proven treatment.
Resmetirom (brand name Rezdiffra), a thyroid hormone receptor-beta agonist, became the first FDA-approved drug specifically for MASH with fibrosis in 2024. It reduces liver fat and fibrosis stage in patients with F2–F3 fibrosis. GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) have shown significant benefit for MASLD with obesity. These are not for all fatty liver patients — patient selection, fibrosis staging, and metabolic profile determine eligibility. Dr. Srinivas will evaluate whether these medications are appropriate for your specific situation.